Welcome to our dedicated page for CANTA news (Ticker: CANTA), a resource for investors and traders seeking the latest updates and insights on CANTA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CANTA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CANTA's position in the market.
Cantargia (STO:CANTA) presented positive results from two clinical trials of nadunolimab combination therapy at the ESMO Congress 2024. The trials, involving 55 patients primarily with lung cancer and head and neck cancer, showed encouraging median survival times in patients previously treated with immunotherapy. Key findings include:
1. CANFOUR trial (40 NSCLC patients): Stronger efficacy in 2nd line patients, especially non-squamous (ORR 91%, OS 26.7 months).
2. CIRIFOUR trial (15 heavily pretreated patients): Median survival of 19.7 months and disease control rate of 60%.
The data suggest nadunolimab's potential in addressing unmet medical needs, particularly in patients who have progressed on checkpoint inhibitors like pembrolizumab.
